Painless blood test could replace bone marrow biopsy for MPN patients

NCT ID NCT07648433

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop a new blood test that could replace the invasive bone marrow biopsy currently used to diagnose myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will collect blood samples from 500 adults with suspected or confirmed MPN and analyze specific blood cells to see if they can accurately detect the disease. If successful, this test could make diagnosis faster, less painful, and more accessible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a simple blood test that replaces painful bone marrow biopsies for diagnosing certain blood cancers.

What could go wrong

This is an early observational study, not a treatment trial. The test may not be accurate enough to replace biopsies, and results may take years to confirm.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••